PUBLICATIONS2018-11-12T23:30:51+00:00

PUBLICATIONS

2018

Correani V, Martire S, Mignogna G, Caruso LB, Tempera I, Giorgi A, Grieco M, Mosca L, Schininà ME, Maras B, d’Erme M. Poly(ADP-ribosylated) proteins in β-amyloid peptide-stimulated microglial cells. Biochem Pharmacol. 2018 Nov 8. pii: S0006-2952(18)30453-2. doi: 10.1016/j.bcp.2018.10.026. PubMed 

Hulse M, Caruso LB, Madzo J, Tan Y, Johnson S, Tempera I. Poly(ADP-ribose) polymerase 1 is necessary for coactivating hypoxia-inducible factor-1-dependent gene expression by Epstein-Barr virus latent membrane protein 1. PLoS Pathog. 2018 Nov 5;14(11):e1007394. doi: 10.1371/journal.ppat.1007394. PubMed 

Lupey-Green LN, Caruso LB, Madzo J, Martin KA, Tan Y, Hulse M, Tempera I. PARP1 Stabilizes CTCF Binding and Chromatin Structure To Maintain Epstein-Barr Virus Latency Type. J Virol. 2018 Aug 29;92(18). pii: e00755-18. doi: 10.1128/JVI.00755-18. Print 2018 Sep 15. PubMed

Caruso LB, Martin KA, Lauretti E, Hulse M, Siciliano M, Lupey-Green LN, Abraham A, Skorski T, Tempera I. Poly(ADP-ribose) Polymerase 1, PARP1, modifies EZH2 and inhibits EZH2 histone methyltransferase activity after DNA damage. Oncotarget. 2018 doi: 10.18632/oncotarget.24291. PubMed

2017

Maifrede S, Martinez E, Nieborowska-Skorska M, Di Marcantonio D, Hulse M, Le BV, Zhao H, Piwocka K, Tempera I, Sykes SM, Skorski T. MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs. Blood Adv. 2017 Aug  9;1(19):1467-1472. doi: 10.1182/bloodadvances.2017006247. PubMed

Mo X, Zhang H, Preston S, Martin K, Zhou B, Vadalia N, Gamero AM, Soboloff J, Tempera I, Zaidi MR. Interferon-γ Signaling in Melanocytes and Melanoma Cells Regulates Expression of CTLA-4. Cancer Res. 2018 Jan 15;78(2):436-450. doi: 10.1158/0008-5472.CAN-17-1615. PubMed

Maifrede S, Martin K, Podszywalow-Bartnicka P, Sullivan-Reed K, Langer SK, Nejati R, Dasgupta Y, Hulse M, Gritsyuk D, Nieborowska-Skorska M, Lupey-Green LN, Zhao H, Piwocka K, Wasik MA, Tempera I, Skorski T. IGH/MYC Translocation Associates with BRCA2 Deficiency and Synthetic Lethality to PARP1 Inhibitors. Mol Cancer Res. 2017 doi: 10.1158/1541-7786.MCR-16-0468. PubMed

Giorgi A, Tempera I, Napoletani G, Drovandi D, Potest√† C, Martire S, Mandosi E, Filardi T, Schinina E, M, Morano S, d’Erme M, Maras B. Poly(ADP-ribosylated) proteins in mononuclear cells from patients with type 2 diabetes identified by proteomic studies. Acta Diabetol. 2017 doi: 10.1007/s00592-017-1013-y. PubMed

Lupey-Green LN, Moquin SA, Martin KA, McDevitt SM, Hulse M, Caruso LB, Pomerantz RT, Miranda JL, Tempera I. PARP1 restricts Epstein Barr Virus lytic reactivation by binding the BZLF1 promoter. Virology. 2017 Jul;507:220-230. doi:  10.1016/j.virol.2017.04.006. PubMed

Wang Y, Santerre M, Tempera I, Martin K, Mukerjee R, Sawaya BE. HIV-1 Vpr disrupts mitochondria axonal transport and accelerates neuronal aging. Neuropharmacology. 2017 doi: 10.1016/j.neuropharm.2017.02.008. PubMed

2016

Samakai E, Hooper R, Martin KA, Shmurak M, Zhang Y, Kappes DJ, Tempera I, Soboloff J. Novel STIM1-dependent control of Ca2+ clearance regulates NFAT activity during T-cell activation. FASEB J. 2016. PubMed

Singh N, Johnstone DB, Martin KA, Tempera I, Kaplan MJ, Denny MF. Alterations in nuclear structure promote lupus autoimmunity in a mouse model. Dis Model Mech. 2016. doi: 10.1242/dmm.024851 PubMed

Martin KA, Lupey LN, Tempera I. Epstein-Barr Virus Oncoprotein LMP1 Mediates Epigenetic Changes in Host Gene Expression through PARP1. J Virol. 2016 doi: 10.1128/JVI.01180-16. PubMed

2015

Tempera I, De Leo A, Kossenkov AV, Cesaroni M, Song H, Dawany N, Showe L, Lu F, Wikramasinghe P, Lieberman PM. Identification of MEF2B, EBF1, and IL6R as Direct Gene Targets of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Critical for EBV-Infected B-Lymphocyte Survival. J Virol. 2015 Oct 14;90(1):345-55. doi: 10.1128/JVI.02318-15. PubMed

Martin KA, Cesaroni M, Denny MF, Lupey LN, Tempera I. Global Transcriptome Analysis Reveals That Poly(ADP-Ribose) Polymerase 1 Regulates Gene Expression through EZH2. Mol Cell Biol. 2015 doi: 10.1128/MCB.00635-15. PubMed

2014

Tempera I, Lieberman PM. Epigenetic regulation of EBV persistence and oncogenesis. Semin Cancer Biol. 2014 doi:10.1016/j.semcancer.2014.01.003 PubMed

Lu F, Tempera I, Lee HT, Dewispelaere K, Lieberman PM. EBNA1 binding and epigenetic regulation of gastrokine tumor suppressor genes in gastric carcinoma cells. Virol J. 2014 Jan 24;11:12. doi: 10.1186/1743-422X-11-12. PubMed

Chen HS, Martin KA, Lu F, Lupey LN, Mueller JM, Lieberman PM, Tempera I. Epigenetic deregulation of the LMP1/LMP2 locus of Epstein-Barr virus by mutation of a single CTCF-cohesin binding site. J Virol. 2014 Feb;88(3):1703-13. doi:10.1128/JVI.02209-13 PubMed

Plasschaert RN, Vigneau S, Tempera I, Gupta R, Maksimoska J, Everett L, Davuluri R, Mamorstein R, Lieberman PM, Schultz D, Hannenhalli S, Bartolomei MS. CTCF binding site sequence differences are associated with unique regulatory and  functional trends during embryonic stem cell differentiation. Nucleic Acids Res. 2014 doi: 10.1093/nar/gkt910. PubMed

2013

Martire S, Fuso A, Rotili D, Tempera I, Giordano C, De Zottis I, Muzi A, Vernole P, Graziani G, Lococo E, Faraldi M, Maras B, Scarpa S, Mosca L, d’Erme M. PARP-1 modulates amyloid beta peptide-induced neuronal damage. PLoS One. 2013 doi: 10.1371/journal.pone.0072169. PubMed

Arvey A, Tempera I, Lieberman PM. Interpreting the Epstein-Barr Virus (EBV) epigenome using high-throughput data. Viruses. 2013. doi: 10.3390/v5041042. PubMed

Arvey A, Tempera I, Tsai K, Chen HS, Tikhmyanova N, Klichinsky M, Leslie C, Lieberman PM. An atlas of the Epstein-Barr virus transcriptome and epigenome reveals host-virus regulatory interactions. Cell Host Microbe. 2012. doi: 10.1016/j.chom.2012.06.008. PubMed